Pembrolizumab and lenvatinib for anaplastic thyroid cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anaplastic thyroid cancer that cannot be removed completely with surgery.
- You are 18 years old or older.
- You are able to care for yourself and are not bedridden (ECOG score 0-2).
- Your organs (like liver, kidneys, bone marrow) are working well enough.
- You have not had a specific BRAF mutation treated with targeted pills before.
- You do not have active bleeding, open wounds, or tumor growing into major blood vessels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a second course of targeted therapy (dabrafenib and trametinib) combined with chemotherapy can help people with a specific type of aggressive thyroid cancer (BRAF-positive anaplastic thyroid cancer) whose tumors stopped responding to initial targeted therapy.
This trial tests a combination of two drugs, zanzalintinib and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer that has not spread to the brain or been treated with similar drugs. The study aims to see if this combination can help shrink or control the cancer.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.